{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:46:31Z","timestamp":1791744391811,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03325-0","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:47:53Z","timestamp":1780062473000},"page":"1910-1929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of different doses of intravenous thrombolytics in acute ischemic stroke: a GRADE-assessed network meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"59","author":[{"given":"Haneen","family":"Sabet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moaz\u00a0Elsayed","family":"Abouelmagd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Shata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Moslemani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Kadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Essam","family":"Abo-elnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramanathan","family":"Kadirvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherief","family":"Ghozy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"3325_CR1","doi-asserted-by":"publisher","unstructured":"GBD (2019) Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 20 795\u2013820. https:\/\/doi.org\/10.1016\/S1474-4422(21)00252-0","DOI":"10.1016\/S1474-4422(21)00252-0"},{"key":"#cr-split#-3325_CR2.1","unstructured":"Baig MU, Bodle J (2026) Thrombolytic Therapy. StatPearls. StatPearls Publishing"},{"key":"#cr-split#-3325_CR2.2","unstructured":"2023 [cited 2026 Mar 21]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557411\/. Accessed 21 Mar"},{"key":"3325_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1161\/STROKEAHA.112.674622","volume":"44","author":"B Frank","year":"2013","unstructured":"Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A et al (2013) Thrombolysis in stroke despite contraindications or warnings? Stroke 44:727\u2013733. https:\/\/doi.org\/10.1161\/STROKEAHA.112.674622","journal-title":"Stroke"},{"key":"3325_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200221","volume":"14","author":"C Streib","year":"2024","unstructured":"Streib C (2024) Tenecteplase for acute ischemic stroke thrombolysis: practical considerations and real-world implementation. Neurol Clin Pract 14:e200221. https:\/\/doi.org\/10.1212\/CPJ.0000000000200221","journal-title":"Neurol Clin Pract"},{"key":"3325_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ihj.2019.09.011","volume":"71","author":"KR Nishanth","year":"2019","unstructured":"Nishanth KR, Math RS, Shankar M, Ravindranath KS, Manjunath CN (2019) Thrombolysis with reteplase in acute pulmonary embolism. Indian Heart J 71:464\u2013467. https:\/\/doi.org\/10.1016\/j.ihj.2019.09.011","journal-title":"Indian Heart J"},{"key":"3325_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1538-7836.2007.02453.x","volume":"5","author":"R Pannell","year":"2007","unstructured":"Pannell R, Kung W, Gurewich V (2007) C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis. J Thromb Haemost 5:1047\u20131054","journal-title":"J Thromb Haemost"},{"key":"3325_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/10760296251328025","volume":"31","author":"AA Alzahrani","year":"2025","unstructured":"Alzahrani AA, Maiz AA, Ibrahim AA, Rifai M, Sanad Alotibi S, Salem L et al (2025) Efficacy and safety of Recombinant Human Prourokinase in acute ischemic stroke: A systematic review and meta-analysis. Clin Appl Thromb Hemost 31:10760296251328025. https:\/\/doi.org\/10.1177\/10760296251328025","journal-title":"Clin Appl Thromb Hemost"},{"key":"3325_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15050466","volume":"15","author":"H Sabet","year":"2025","unstructured":"Sabet H, Abbas A, El-Moslemani M, Zanaty MA, Kadirvel R, Ghozy S (2025) Efficacy and safety of Recombinant Human Prourokinase in acute ischemic stroke: A systematic review and meta-analysis of randomized controlled trials. Brain Sci 15:466. https:\/\/doi.org\/10.3390\/brainsci15050466","journal-title":"Brain Sci"},{"key":"3325_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02983-9","volume":"30","author":"AM Hagag","year":"2025","unstructured":"Hagag AM, Kormod ME, Ads ME, El-Refaay MA, Abozaid OM, Ghanem OA et al (2025) Tenecteplase versus alteplase in patients with acute ischemic stroke: an updated systematic review and meta-analysis. Eur J Med Res 30:726. https:\/\/doi.org\/10.1186\/s40001-025-02983-9","journal-title":"Eur J Med Res"},{"key":"3325_CR10","unstructured":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations | EQUATOR Network. [cited 2025 June 21]. https:\/\/www.equator-network.org\/reporting-guidelines\/prisma-extension-network-meta-analyses\/. Accessed 21 June 2025"},{"key":"3325_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"3325_CR12","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ British Medical J Publ Grp 343:5928","journal-title":"BMJ British Medical J Publ Grp"},{"key":"3325_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5630","volume":"349","author":"MA Puhan","year":"2014","unstructured":"Puhan MA, Sch\u00fcnemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA et al (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349:g5630. https:\/\/doi.org\/10.1136\/bmj.g5630","journal-title":"BMJ"},{"key":"3325_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","volume":"150","author":"L Zeng","year":"2022","unstructured":"Zeng L, Brignardello-Petersen R, Hultcrantz M, Mustafa RA, Murad MH, Iorio A et al (2022) GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol 150:216\u2013224. https:\/\/doi.org\/10.1016\/j.jclinepi.2022.07.014","journal-title":"J Clin Epidemiol"},{"key":"3325_CR15","unstructured":"R\u00fccker G, Krahn U, K\u00f6nig J, Efthimiou O, Davies A, Papakonstantinou T et al (2025) netmeta Network Meta-Analysis using Frequentist Methods. 2025 [cited 2025 June 21]. https:\/\/cran.r-project.org\/web\/packages\/netmeta\/index.html. Accessed 21 June 2025"},{"key":"3325_CR16","unstructured":"S9-L Identifying and addressing inconsistency in network meta-analysis.pdf. [cited 2025 June 21]. https:\/\/methods.cochrane.org\/cmi\/sites\/methods.cochrane.org.cmi\/files\/uploads\/S9-L%20Identifying%20and%20addressing%20inconsistency%20in%20network%20meta-analysis.pdf. Accessed 21 June 2025"},{"key":"3325_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15:58. https:\/\/doi.org\/10.1186\/s12874-015-0060-8","journal-title":"BMC Med Res Methodol"},{"key":"3325_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"3325_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A (2024) Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol 24:243. https:\/\/doi.org\/10.1186\/s12874-024-02356-6","journal-title":"BMC Med Res Methodol"},{"key":"3325_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/nejmoa1109842","volume":"366","author":"M Parsons","year":"2012","unstructured":"Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F et al (2012) A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 366:1099\u20131107. https:\/\/doi.org\/10.1056\/nejmoa1109842","journal-title":"N Engl J Med"},{"key":"3325_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/s1474-4422(15)70017-7","volume":"14","author":"X Huang","year":"2015","unstructured":"Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A et al (2015) Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. The Lancet Neurol Elsevier BV 14:368\u2013376. https:\/\/doi.org\/10.1016\/s1474-4422(15)70017-7","journal-title":"The Lancet Neurol Elsevier BV"},{"key":"3325_CR22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/s1474-4422(22)00171-5","volume":"21","author":"A Bivard","year":"2022","unstructured":"Bivard A, Zhao H, Churilov L, Campbell BCV, Coote S, Yassi N et al (2022) Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial. The Lancet Neurol Elsevier BV 21:520\u2013527. https:\/\/doi.org\/10.1016\/s1474-4422(22)00171-5","journal-title":"The Lancet Neurol Elsevier BV"},{"key":"3325_CR23","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jama.2020.1511","volume":"323","author":"BCV Campbell","year":"2020","unstructured":"Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ et al (2020) Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: The EXTEND-IA TNK Part 2 randomized clinical trial. JAMA. Am Med Assoc (AMA) 323:1257. https:\/\/doi.org\/10.1001\/jama.2020.1511","journal-title":"JAMA. Am Med Assoc (AMA)"},{"key":"3325_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s12975-022-01012-9","volume":"13","author":"H Song","year":"2022","unstructured":"Song H, Wang Y, Ma Q, Chen H, Liu B, Yang Y et al (2022) Efficacy and safety of recombinant human prourokinase in acute ischemic stroke: a phase IIa randomized clinical trial. Transl Stroke Res 13:995\u20131004. https:\/\/doi.org\/10.1007\/s12975-022-01012-9","journal-title":"Transl Stroke Res"},{"key":"3325_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.25415","volume":"6","author":"H Song","year":"2023","unstructured":"Song H, Wang Y, Ma Q, Feng W, Liu R, Lv X et al (2023) Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial. JAMA Netw Open 6:e2325415. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.25415","journal-title":"JAMA Netw Open"},{"key":"3325_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0140-6736(22)01054-6","volume":"400","author":"BK Menon","year":"2022","unstructured":"Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB et al (2022) Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. The Lancet Elsevier BV 400:161\u2013169. https:\/\/doi.org\/10.1016\/s0140-6736(22)01054-6","journal-title":"The Lancet Elsevier BV"},{"key":"3325_CR27","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/nejmoa1515510","volume":"374","author":"CS Anderson","year":"2016","unstructured":"Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee TH et al (2016) Low-dose versus standard-dose intravenous Alteplase in acute ischemic stroke. N Engl J Med 374:2313\u20132323. https:\/\/doi.org\/10.1056\/nejmoa1515510","journal-title":"N Engl J Med"},{"key":"3325_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1161\/strokeaha.109.572040","volume":"41","author":"EC Haley","year":"2010","unstructured":"Haley EC, Thompson JLP, Grotta JC, Lyden PD, Hemmen TG, Brown DL et al (2010) Phase IIB\/III Trial of Tenecteplase in Acute Ischemic Stroke: Results of a Prematurely Terminated Randomized Clinical Trial. Stroke Ovid Technol (Wolters Kluwer Health) 41:707\u2013711. https:\/\/doi.org\/10.1161\/strokeaha.109.572040","journal-title":"Stroke Ovid Technol (Wolters Kluwer Health)"},{"key":"3325_CR29","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1056\/nejmoa2400314","volume":"390","author":"S Li","year":"2024","unstructured":"Li S, Gu H-Q, Li H, Wang X, Jin A, Guo S et al (2024) Reteplase versus Alteplase for acute ischemic stroke. N Engl J Med 390:2264\u20132273. https:\/\/doi.org\/10.1056\/nejmoa2400314. (Mass Medical Soc)","journal-title":"N Engl J Med"},{"key":"3325_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s1474-4422(24)00436-8","volume":"24","author":"S Li","year":"2025","unstructured":"Li S, Gu H-Q, Feng B, Li H, Wang X, Dong Q et al (2025) Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4\u00b75 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial. The Lancet Neurol Elsevier BV 24:33\u201341. https:\/\/doi.org\/10.1016\/s1474-4422(24)00436-8","journal-title":"The Lancet Neurol Elsevier BV"},{"key":"3325_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1161\/strokeaha.123.045193","volume":"55","author":"S Li","year":"2024","unstructured":"Li S, Wang X, Jin A, Liu G, Gu H, Li H et al (2024) Safety and efficacy of reteplase versus alteplase for acute ischemic stroke: a phase 2 randomized controlled trial. Stroke Ovid Technol (Wolters Kluwer Health) 55:366\u2013375. https:\/\/doi.org\/10.1161\/strokeaha.123.045193","journal-title":"Stroke Ovid Technol (Wolters Kluwer Health)"},{"key":"3325_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/svn-2021-000978","volume":"7","author":"S Li","year":"2022","unstructured":"Li S, Pan Y, Wang Z, Liang Z, Chen H, Wang D et al (2022) Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study. Stroke Vasc Neurol BMJ 7:47\u201353. https:\/\/doi.org\/10.1136\/svn-2021-000978","journal-title":"Stroke Vasc Neurol BMJ"},{"key":"3325_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/svn-2023-002820","volume":"9","author":"X Cheng","year":"2024","unstructured":"Cheng X, Hong L, Churilov L, Lin L, Ling Y, Zhang J et al (2024) Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial. Stroke Vasc Neurol 9:551\u2013559. https:\/\/doi.org\/10.1136\/svn-2023-002820","journal-title":"Stroke Vasc Neurol"},{"key":"3325_CR34","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/nejmoa1716405","volume":"378","author":"BCV Campbell","year":"2018","unstructured":"Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ et al (2018) Tenecteplase versus Alteplase before thrombectomy for ischemic stroke. N Engl J Med 378:1573\u20131582. https:\/\/doi.org\/10.1056\/nejmoa1716405","journal-title":"N Engl J Med"},{"key":"3325_CR35","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/s1474-4422(24)00377-6","volume":"23","author":"KW Muir","year":"2024","unstructured":"Muir KW, Ford GA, Ford I, Wardlaw JM, McConnachie A, Greenlaw N et al (2024) Tenecteplase versus Alteplase for acute stroke within 4\u00b75 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol 23:1087\u20131096. https:\/\/doi.org\/10.1016\/s1474-4422(24)00377-6","journal-title":"Lancet Neurol"},{"key":"3325_CR36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/s1474-4422(17)30253-3","volume":"16","author":"N Logallo","year":"2017","unstructured":"Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, R\u00f8nning OM et al (2017) Tenecteplase versus Alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol 16:781\u2013788. https:\/\/doi.org\/10.1016\/s1474-4422(17)30253-3","journal-title":"Lancet Neurol"},{"key":"3325_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/s1474-4422(22)00124-7","volume":"21","author":"CE Kvistad","year":"2022","unstructured":"Kvistad CE, N\u00e6ss H, Helleberg BH, Idicula T, Hagberg G, Nordby LM et al (2022) Tenecteplase versus Alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol 21:511\u2013519. https:\/\/doi.org\/10.1016\/s1474-4422(22)00124-7","journal-title":"Lancet Neurol"},{"key":"3325_CR38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/s1474-4422(24)00206-0","volume":"23","author":"MW Parsons","year":"2024","unstructured":"Parsons MW, Yogendrakumar V, Churilov L, Garcia-Esperon C, Campbell BCV, Russell ML et al (2024) Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4\u00b75 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. Lancet Neurol Elsevier BV 23:775\u2013786. https:\/\/doi.org\/10.1016\/s1474-4422(24)00206-0","journal-title":"Lancet Neurol Elsevier BV"},{"key":"3325_CR39","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/s0140-6736(22)02600-9","volume":"401","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV et al (2023) Tenecteplase versus Alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet 401:645\u2013654. https:\/\/doi.org\/10.1016\/s0140-6736(22)02600-9","journal-title":"Lancet"},{"key":"3325_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.14721","volume":"332","author":"X Meng","year":"2024","unstructured":"Meng X, Li S, Dai H, Lu G, Wang W, Che F et al (2024) Tenecteplase vs Alteplase for patients with acute ischemic stroke: The ORIGINAL randomized clinical trial. JAMA 332:1437. https:\/\/doi.org\/10.1001\/jama.2024.14721","journal-title":"JAMA"},{"key":"3325_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ajem.2025.04.024","volume":"96","author":"A Alkhiri","year":"2025","unstructured":"Alkhiri A, Salamatullah HK, Alturki F, Alamri AF, Almaghrabi AA, Alshaikh H et al (2025) Reteplase versus alteplase for acute ischemic stroke: meta-analysis. Am J Emerg Med 96:52\u201357. https:\/\/doi.org\/10.1016\/j.ajem.2025.04.024","journal-title":"Am J Emerg Med"},{"key":"3325_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108338","volume":"34","author":"M Ifzaal","year":"2025","unstructured":"Ifzaal M, Bughio SA, Rizvi SAFA, Muzaffar M, Ali R, Ikram M et al (2025) Efficacy and safety of Tenecteplase administration in extended time window for acute ischemic stroke: an updated meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis 34:108338. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2025.108338","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"3325_CR43","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40120-024-00684-9","volume":"14","author":"Y Hu","year":"2025","unstructured":"Hu Y, Wu S, Zhang H, Wang K, Zhang L, Ma Y et al (2025) Efficacy and safety of various intravenous thrombolytics for acute ischemic stroke (AIS) at various dosages: a systematic review and network meta-analysis. Neurol Ther 14:491\u2013523. https:\/\/doi.org\/10.1007\/s40120-024-00684-9","journal-title":"Neurol Ther"},{"key":"3325_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074495","author":"A Izcovich","year":"2023","unstructured":"Izcovich A, Chu DK, Mustafa RA, Guyatt G, Brignardello-Petersen R (2023) A guide and pragmatic considerations for applying GRADE to network meta-analysis. BMJ. https:\/\/doi.org\/10.1136\/bmj-2022-074495","journal-title":"BMJ"},{"key":"3325_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000525869","volume":"52","author":"L Si","year":"2023","unstructured":"Si L, Chen X, Ouyang M, Wang X, Chen G, Cao Y et al (2023) Cost-effectiveness of low-dose compared to standard-dose Alteplase for acute ischemic stroke in China: a within-trial economic evaluation of the ENCHANTED study. Cerebrovasc Dis 52:145\u2013152. https:\/\/doi.org\/10.1159\/000525869","journal-title":"Cerebrovasc Dis"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03325-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03325-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03325-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:36:58Z","timestamp":1791743818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03325-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3325"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03325-0","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","label":"Consent to publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sherief Ghozy, Abdallah Abbas, Ramanathan Kadirvel.","order":4,"name":"Ethics","label":"Final revision","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that no part of this manuscript was written using AI.","order":5,"name":"Ethics","label":"Generative AI in scientific writing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We affirm that this research paper has not been previously published in any other academic journal or platform.","order":6,"name":"Ethics","label":"Previous publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}